Negative symptoms of schizophrenia: contribution of IL-1β, IL-4, and IL-10 gene polymorphisms and adverse childhood experiences
|
Full Text:
Subscribers Only
|
Suggested citation:
Mikhaylova VA, Alfimova MV, Plakunova VV, et al. [Negative symptoms of schizophrenia: contribution of IL-1β, IL-4, and IL-10 gene polymorphisms and adverse childhood experiences]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2024;(4):48-54. Russian
In this one-stage experimental study to investigate the differential association of polymorphisms of interleukin genes IL-1β (rs16944), IL-4 (rs2243250), and IL-10 (rs1800872, rs1800896) and adverse childhood experiences with negative symptoms of schizophrenia, particularly the factors of avolition-apathy and diminished expression, data from 564 patients diagnosed with schizophrenia or schizoaffective disorder were analyzed. Results indicate that the high-expressive allele of IL-1β and low-expressive alleles of IL-4 and IL-10 are associated with more severe negative symptoms. However, a differentiated association with the avolition-apathy and diminished expression factors was found only for the IL-10 rs1800872 polymorphism. Among carriers of the low-expressive AA allele with adverse childhood experiences, there is a trend towards increased diminished expression scores, but not avolition-apathy scores. The findings confirm that the imbalance between pro-inflammatory and anti-inflammatory cytokines may be a key mechanism influencing the severity and heterogeneity of negative symptoms.
Keywords genetic polymorphism; negative symptoms; neuroinflammation; adverse childhood experiences; schizophrenia
1. Stanculete MF, Capatina O. The Many Faces of Negative Symptoms in Schizophrenia. In: Psychosis – Phenomenology, Psychopathology and Pathophysiology. K Fukao, editor. London: IntechOpen; 2021. 19 p. DOI: 10.5772/intechopen.98412 2. Strauss GP, Horan WP, Kirkpatrick B, et al. Deconstructing negative symptoms of schizophrenia: avolition-apathy and diminished expression clusters predict clinical presentation and functional outcome. J Psychiatr Res. 2013;47(6):783–90. DOI: 10.1016/j.jpsychires.2013.01.015 3. Krynicki CR, Dazzan P, Pariante CM, et al. Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment. Brain Behav Immun. 2021;91:498–504. DOI: 10.1016/j.bbi.2020.10.026 4. Bègue I, Kaiser S, Kirschner M. Pathophysiology of negative symptom dimensions of schizophrenia – Current developments and implications for treatment. Neurosci Biobehav Rev. 2020;116:74–88. DOI: 10.1016/j.neubiorev.2020.06.004 5. Golimbet V, Lezheiko T, Mikhailova V, et al. A study of the association between polymorphisms in the genes for interleukins IL-6 and IL-10 and negative symptoms subdomains in schizophrenia. Indian J Psychiatry. 2022;64(5):484–8. DOI: 10.4103/indianjpsychiatry.indianjpsychiatry_212_22 6. Dennison U, McKernan D, Cryan J, et al. Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype. Psychol Med. 2012;42(9):1865–71. DOI: 10.1017/S0033291712000074 7. Lim K, Peh O-H, Yang Z, et al. Large-scale evaluation of the Positive and Negative Syndrome Scale (PANSS) symptom architecture in schizophrenia. Asian J Psychiatr. 2021;62:102732. DOI: 10.1016/j.ajp.2021.102732 8. Alfimova MV, Korovaitseva GI, Gabaeva MV, et al. [Genetic polymorphism of cytokines IL-1β, IL-4 and TNF-α as a factor modifying the impact of childhood adversity on schizophrenia symptoms]. Zh Nevrol Psikhiatr Im SS Korsakova. 2022;122(9):110–7. (In Russ.) DOI: 10.17116/jnevro2022122091110 9. Akkad DA, Arning L, Ibrahim SM, et al. Sex specifically associated promoter polymorphism in multiple sclerosis affects interleukin 4 expression levels. Genes Immun. 2007;8(8):703–6. DOI: 10.1038/sj.gene.6364429 10. GTEx Consortium. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348(6235):648–60. DOI: 10.1126/science.1262110 11. Võsa U, Claringbould A, Westra HJ, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021;53(9):1300–10. DOI: 10.1038/s41588-021-00913-z 12. Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2012;40(D1):D930–4. DOI: 10.1093/nar/gkr917 13. Zeller T, Wild P, Szymczak S, et al. Genetics and beyond--the transcriptome of human monocytes and disease susceptibility. PLoS One. 2010;5(5):e10693. DOI: 10.1371/journal.pone.0010693 14. Suhre K, Shin SY, Petersen AK, et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature. 2011;477(7362):54–60. DOI: 10.1038/nature10354 15. Westra HJ, Peters MJ, Esko T, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet. 2013;45(10):1238–43. DOI: 10.1038/ng.2756 16. Moga C-I, Pavăl D, Micluția IV. Outlining the absence: from inflammation to a distinctendophenotype for the negative symptoms of schizophrenia. Psychiatr Danub. 2024;36(2):161–73. DOI: 10.24869/psyd.2024.161 17. Dunleavy C, Elsworthy RJ, Upthegrove R, et al. Inflammation in first-episode psychosis: The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta-analysis. Acta Psychiatr Scand. 2022;146(1):6–20. DOI: 10.1111/acps.13416
Article Metrics
Metrics powered by PLOS ALM